Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB – Get Free Report)’s share price crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $0.00 and traded as high as $0.56. Hemispherx BioPharma shares last traded at $0.48, with a volume of 215,153 shares.
Hemispherx BioPharma Stock Performance
Hemispherx BioPharma Company Profile
Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).
Read More
- Five stocks we like better than Hemispherx BioPharma
- 5 Top Rated Dividend Stocks to Consider
- Silicon Motion Proves That AI in Motion Stays in Motion
- Investing In Automotive Stocks
- Undervalued UnitedHealth Group Won’t Be For Long
- What is a SEC Filing?
- The 5 Stocks Most Sold By Insiders This Year
Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
